Literature DB >> 26997460

Health policy: Strategies to optimize expedited investigational new drug safety reports.

Apostolia M Tsimberidou1.   

Abstract

Mesh:

Substances:

Year:  2016        PMID: 26997460     DOI: 10.1038/nrclinonc.2016.42

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative.

Authors:  Jonathan P Jarow; Sandra Casak; Meredith Chuk; Lori A Ehrlich; Sean Khozin
Journal:  Clin Cancer Res       Date:  2016-01-18       Impact factor: 12.531

  1 in total
  1 in total

Review 1.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.